Diosgenin, a Novel Aldose Reductase Inhibitor, Attenuates the Galactosemic Cataract in Rats
Joint Authors
Ji, Lixia
Cheng, Lixia
Yang, Zhihong
Source
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-09-05
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Objective.
To seek efficient aldose reductase inhibitors (ARIs) with excellent in vitro and in vivo biological activities against rat galactosemic cataract.
Methods.
The method was firstly optimized to screen strong ARIs from nonoriented synthetic compounds and natural extracts.
Then, diosgenin was assessed on osmotic expansion of primarily cultured lens epithelial cells (LECs) induced by galactose (50 mM).
Diosgenin was administered to galactosemic rats by oral (100 and 200 mg/kg) or direct drinking (0.1%) to evaluate its anticataract effects.
Results.
Diosgenin was found as the strongest ARI with IC50 of 4.59 × 10−6 mol/L.
Diosgenin (10 μM) evidently inhibited the formation of tiny vacuoles and upregulation of AR mRNA in LECs.
In vivo, diosgenin delayed lens opacification, inhibited the increase of ratio of lens weight to body weight, and decreased AR activity, galactitol level, and AR mRNA expression, especially in the diosgenin drinking (0.1%) group.
Conclusions.
Diosgenin was an efficient ARI, which not only significantly decreased the LECs’ osmotic expansion in vitro but also markedly delayed progression of rat galactosemic cataract in vivo.
Thus, diosgenin rich food can be recommended to diabetic subjects as dietary management to postpone the occurrence of sugar cataract, and diosgenin deserves further investigation for chronic diabetic complications.
American Psychological Association (APA)
Ji, Lixia& Cheng, Lixia& Yang, Zhihong. 2017. Diosgenin, a Novel Aldose Reductase Inhibitor, Attenuates the Galactosemic Cataract in Rats. Journal of Diabetes Research،Vol. 2017, no. 2017, pp.1-9.
https://search.emarefa.net/detail/BIM-1174695
Modern Language Association (MLA)
Ji, Lixia…[et al.]. Diosgenin, a Novel Aldose Reductase Inhibitor, Attenuates the Galactosemic Cataract in Rats. Journal of Diabetes Research No. 2017 (2017), pp.1-9.
https://search.emarefa.net/detail/BIM-1174695
American Medical Association (AMA)
Ji, Lixia& Cheng, Lixia& Yang, Zhihong. Diosgenin, a Novel Aldose Reductase Inhibitor, Attenuates the Galactosemic Cataract in Rats. Journal of Diabetes Research. 2017. Vol. 2017, no. 2017, pp.1-9.
https://search.emarefa.net/detail/BIM-1174695
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1174695